Welcome to our dedicated page for Cadrenal Therapeutics news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therapeutics stock.
Cadrenal Therapeutics develops biopharmaceutical therapies for life-threatening immune and thrombotic conditions. News about Cadrenal Therapeutics centers on CAD-1005, its investigational selective 12-lipoxygenase inhibitor for heparin-induced thrombocytopenia, including clinical-study results, FDA communications, pivotal-trial design guidance, and research involving the broader 12-LOX inhibitor platform.
Company updates also cover pipeline assets such as tecarfarin, an oral vitamin K antagonist for chronic anticoagulation settings, and frunexian, a parenteral Factor XIa inhibitor for acute hospital use. Recurring financial news includes quarterly results, cash resources, equity financings, and strategic alternatives tied to the company’s clinical development plans.
Cadrenal Therapeutics (CVKD)/b) will participate in H.C. Wainwright's 28th Annual Global Investment Conference from September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.A pre-recorded presentation will be available on demand via the conference portal starting September 11, 2026, at 7:00 a.m. ET, with slides posted on Cadrenal's investor relations website. CEO Quang X. Pham is expected to discuss the Cardiac Acute Critical Care Franchise, the structured partnering process for CAD-1005, frunexian and tecarfarin, and recent Phase 2 clinical data on CAD-1005. Mr. Pham will also be available for one-on-one investor meetings during the conference.
Cadrenal Therapeutics (Nasdaq: CVKD) reported a positive outcome from a July 28, 2026 FDA Type D meeting on the Phase 3 registration study of CAD-1005, a first-in-class 12-lipoxygenase inhibitor in development for heparin-induced thrombocytopenia (HIT). The FDA and Cadrenal aligned on key elements of the protocol and Statistical Analysis Plan, including an optimized composite primary endpoint based on adjudicated new or worsening thromboembolic events in Serotonin Release Assay-positive patients through Day 14 or hospital discharge.
According to Cadrenal Therapeutics, the FDA also agreed to a placebo-controlled design with standard anticoagulation in both arms and to assess bleeding as a major safety endpoint using International Society on Thrombosis and Haemostasis criteria, providing greater clarity on the regulatory path for CAD-1005’s Phase 3 program.
Cadrenal Therapeutics (Nasdaq: CVKD) reported second quarter 2026 results and detailed progress across its Cardiac Acute Critical Care Franchise. Late-breaking Phase 2 data for CAD-1005 presented at the ISTH 2026 Congress showed a randomized, blinded, placebo-controlled study with an absolute reduction of more than 25% in thrombotic events when CAD-1005 was added to standard anticoagulant therapy, alongside a favorable safety profile and renal-protective baseline.
Cadrenal launched a structured partnering process to explore development, licensing and commercialization deals for CAD-1005, frunexian and tecarfarin, signed an agreement with a global non-dilutive funding specialist, and completed a private placement generating approximately $3.0 million in gross proceeds. Q2 2026 operating expenses declined to $3.3 million from $3.7 million a year earlier, with net loss narrowing to $3.3 million from $3.7 million. According to Cadrenal, cash and cash equivalents were about $4.2 million in early August 2026, expected to fund operations through the first quarter of 2027, though not sufficient to bring product candidates to clinical trial readiness.
Cadrenal Therapeutics (Nasdaq: CVKD) outlined a consolidated multi-indication strategy for its Cardiac Acute Critical Care franchise centered on CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI).
Following the discontinuation of a competitor’s late-stage Phase 3 CSA-AKI trial for lack of efficacy, the company is positioning CAD-1005, a 12-lipoxygenase (12-LOX) inhibitor, for first-in-class potential in the $1 billion+ U.S. CSA-AKI market. CAD-1005 is being studied as a “post-operative shield” intended to reduce platelet hyperactivation in HIT and inflammation-driven injury in CSA-AKI. Late-breaking Phase 2 data presented at ISTH 2026 showed an absolute reduction in thrombotic events greater than 25% with a favorable safety and renal-protective baseline. Cadrenal is pursuing global strategic partnerships, including out-licensing or co-development, for this Phase 3-ready critical care asset.
Cadrenal Therapeutics (Nasdaq: CVKD) has aligned its clinical portfolio into a Cardiac Acute Critical Care Franchise and launched a structured process to seek out-licensing, portfolio monetization, or co-development partnerships for its late-stage assets CAD-1005, frunexian and tecarfarin.
The franchise is organized into three pillars: Phase 2-ready IV Factor XIa inhibitor frunexian for pre-operative safety in HIT-susceptible CABG patients; Phase 3-ready orphan-focused programs including tecarfarin; and Phase 3-ready IV 12-LOX inhibitor CAD-1005 for post-operative HIT. Recently presented Phase 2 data for CAD-1005 at ISTH 2026 showed an absolute thrombotic event reduction of >25%, with a favorable safety and renal-protective baseline. Cadrenal is also advancing tecarfarin into rare pediatric indications and maintaining development in ESKD and LVADs, while progressing CAD-2000, a preclinical oral 12-LOX inhibitor for chronic cardiorenal inflammatory and thrombotic conditions.
Cadrenal Therapeutics (Nasdaq: CVKD) reported late-breaking Phase 2 data for first-in-class 12-LOX inhibitor CAD-1005 in heparin-induced thrombocytopenia (HIT) at the ISTH 2026 Congress in Paris. In the first randomized, blinded, placebo-controlled HIT trial, CAD-1005 showed an absolute reduction of more than 25% in new or worsening thrombotic events versus placebo (50% vs >75%).
The study, which was not powered for statistical significance, also showed no serious adverse events attributable to CAD-1005, no major bleeding in SRA+ patients, and no deaths. CAD-1005 is described as Phase 3‑ready, targets a life-threatening immune-mediated clotting disorder with an estimated $2 billion peak annual revenue opportunity, and holds FDA Orphan Drug and Fast Track designations as well as EMA Orphan Drug status.
Cadrenal Therapeutics (Nasdaq: CVKD) entered a definitive agreement for a private placement of 960,000 common shares (or pre-funded warrants) plus series C-1 and C-2 warrants for up to 1,920,000 additional shares, at a combined $3.125 per share, raising expected gross proceeds of $3 million.
Total potential gross proceeds, including full cash exercise of all warrants, are about $8.8 million. According to Cadrenal Therapeutics, net proceeds are expected to extend the cash runway into Q1 2027, and, with full warrant exercise, into the second half of 2027 to support partnering for tecarfarin in Kawasaki Disease and CAD-1005 in CSA-AKI and HIT.
Cadrenal Therapeutics (Nasdaq: CVKD) announced that late-breaking Phase 2 data for its first-in-class 12-lipoxygenase inhibitor CAD-1005 for heparin-induced thrombocytopenia (HIT) were selected for a prestigious oral presentation at the ISTH 2026 Congress in Paris.
The Phase-3-ready program targets a HIT market with peak annual revenue potential of $2 billion, according to Cadrenal. The study is described as the first-ever randomized, blinded, placebo-controlled trial in HIT.
Cadrenal Therapeutics (Nasdaq: CVKD) plans to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease patients with coronary artery aneurysms needing chronic anticoagulation.
If designation and approval are achieved, Cadrenal could qualify for a transferable Priority Review Voucher, while also advancing its Phase 3‑ready CAD‑1005 12‑LOX inhibitor portfolio under a dual-track partnering strategy.
Cadrenal Therapeutics (Nasdaq: CVKD) plans a Phase 2a proof-of-concept trial of CAD-1005 to prevent cardiac surgery-associated acute kidney injury (CSA-AKI) in high-risk patients, starting later in 2026.
The trial aims to generate safety, renal injury and 12-LOX pathway data relevant to both CSA-AKI and Cadrenal’s Phase 3-ready HIT program, supporting potential non-dilutive pharma partnerships at BIO 2026.